Noiiglutide
A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.
Hengrui · Phase 2 · Completed · Enrollment 128
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| HS-20004 or placebo treatment (Low dose) | T2D only | n/r | 16 | n/r | n/r |
| HS-20004 or placebo treatment (median dose 1) | T2D only | n/r | 16 | n/r | n/r |
| HS-20004 or placebo treatment (median dose 2) | T2D only | n/r | 16 | n/r | n/r |
| HS-20004 or placebo treatment (high dose) | T2D only | n/r | 16 | n/r | n/r |